Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANAVEX LIFE SCIENCES CORP.AVXL · Entity 6086 | Director | May 21, 2021 | May 26, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANAVEX LIFE SCIENCES CORP.
Report date May 21, 2021 · Filed May 26, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2021-05-21 transaction · row 9
9 source rows · reconciled sequenceRow 1 · 2021-05-21 · Exercise / conversion · Acquired 37,500 · Balance 37,500 Row 2 · 2021-05-21 · Exercise / conversion · Acquired 50,000 · Balance 87,500 Row 3 · 2021-05-21 · Exercise / conversion · Acquired 1,500 · Balance 89,000 Row 4 · 2021-05-21 · Exercise / conversion · Acquired 1,500 · Balance 90,500 Row 5 · 2021-05-21 · Exercise / conversion · Acquired 1,500 · Balance 92,000 Row 6 · 2021-05-21 · Exercise / conversion · Acquired 1,500 · Balance 93,500 Row 7 · 2021-05-21 · Exercise / conversion · Acquired 1,500 · Balance 95,000 Row 8 · 2021-05-21 · Exercise / conversion · Acquired 50,000 · Balance 145,000 Row 9 · 2021-05-21 · Sale · Disposed 145,000 · Balance 0 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.20 · Expires 2024-05-07 | Direct | 0 |
Reported balance
After 2021-05-21 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2021-05-21 · Exercise / conversion · Disposed 37,500 · Balance 0 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.92 · Expires 2025-04-02 | Direct | 0 |
Reported balance
After 2021-05-21 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2021-05-21 · Exercise / conversion · Disposed 50,000 · Balance 0 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.64 · Expires 2025-09-30 | Direct | 0 |
Reported balance
After 2021-05-21 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2021-05-21 · Exercise / conversion · Disposed 1,500 · Balance 0 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.57 · Expires 2025-12-31 | Direct | 0 |
Reported balance
After 2021-05-21 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2021-05-21 · Exercise / conversion · Disposed 1,500 · Balance 0 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.90 · Expires 2026-03-31 | Direct | 0 |
Reported balance
After 2021-05-21 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2021-05-21 · Exercise / conversion · Disposed 1,500 · Balance 0 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.66 · Expires 2026-04-27 | Direct | 0 |
Reported balance
After 2021-05-21 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2021-05-21 · Exercise / conversion · Disposed 1,500 · Balance 0 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.11 · Expires 2026-06-30 | Direct | 0 |
Reported balance
After 2021-05-21 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2021-05-21 · Exercise / conversion · Disposed 1,500 · Balance 0 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.96 · Expires 2030-01-06 | Direct | 0 |
Reported balance
After 2021-05-21 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2021-05-21 · Exercise / conversion · Disposed 50,000 · Balance 0 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 21, 2021 Filed May 26, 2021 01:30 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.96 | $0.00 |
DisclosureSEC source: 0001731122-21-000941 · ownership.xml · derivative · entry 17 FAVUS ELLIOT · CIK 0001608022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2030-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2021 Filed May 26, 2021 01:30 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $6.11 | $0.00 |
DisclosureSEC source: 0001731122-21-000941 · ownership.xml · derivative · entry 16 FAVUS ELLIOT · CIK 0001608022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires 2026-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2021 Filed May 26, 2021 01:30 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $5.66 | $0.00 |
DisclosureSEC source: 0001731122-21-000941 · ownership.xml · derivative · entry 15 FAVUS ELLIOT · CIK 0001608022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires 2026-04-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2021 Filed May 26, 2021 01:30 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $4.90 | $0.00 |
DisclosureSEC source: 0001731122-21-000941 · ownership.xml · derivative · entry 14 FAVUS ELLIOT · CIK 0001608022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires 2026-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2021 Filed May 26, 2021 01:30 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $5.57 | $0.00 |
DisclosureSEC source: 0001731122-21-000941 · ownership.xml · derivative · entry 13 FAVUS ELLIOT · CIK 0001608022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires 2025-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2021 Filed May 26, 2021 01:30 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $5.64 | $0.00 |
DisclosureSEC source: 0001731122-21-000941 · ownership.xml · derivative · entry 12 FAVUS ELLIOT · CIK 0001608022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires 2025-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2021 Filed May 26, 2021 01:30 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0001731122-21-000941 · ownership.xml · derivative · entry 11 FAVUS ELLIOT · CIK 0001608022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2025-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2021 Filed May 26, 2021 01:30 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | Exercise / conversionStock Option (Right to Buy) · Derivative | 37,500 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001731122-21-000941 · ownership.xml · derivative · entry 10 FAVUS ELLIOT · CIK 0001608022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,500 shares Expires 2024-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2021 Filed May 26, 2021 01:30 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | SaleCommon Stock | 145,000 | $11.70 | $1,696,282.50 |
DisclosureSEC source: 0001731122-21-000941 · ownership.xml · nonDerivative · entry 9 FAVUS ELLIOT · CIK 0001608022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| May 21, 2021 Filed May 26, 2021 01:30 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | Exercise / conversionCommon Stock | 50,000 | $2.96 | $148,000.00 |
DisclosureSEC source: 0001731122-21-000941 · ownership.xml · nonDerivative · entry 8 FAVUS ELLIOT · CIK 0001608022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2021 Filed May 26, 2021 01:30 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | Exercise / conversionCommon Stock | 1,500 | $6.11 | $9,165.00 |
DisclosureSEC source: 0001731122-21-000941 · ownership.xml · nonDerivative · entry 7 FAVUS ELLIOT · CIK 0001608022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2021 Filed May 26, 2021 01:30 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | Exercise / conversionCommon Stock | 1,500 | $5.66 | $8,490.00 |
DisclosureSEC source: 0001731122-21-000941 · ownership.xml · nonDerivative · entry 6 FAVUS ELLIOT · CIK 0001608022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2021 Filed May 26, 2021 01:30 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | Exercise / conversionCommon Stock | 1,500 | $4.90 | $7,350.00 |
DisclosureSEC source: 0001731122-21-000941 · ownership.xml · nonDerivative · entry 5 FAVUS ELLIOT · CIK 0001608022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2021 Filed May 26, 2021 01:30 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | Exercise / conversionCommon Stock | 1,500 | $5.57 | $8,355.00 |
DisclosureSEC source: 0001731122-21-000941 · ownership.xml · nonDerivative · entry 4 FAVUS ELLIOT · CIK 0001608022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2021 Filed May 26, 2021 01:30 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | Exercise / conversionCommon Stock | 1,500 | $5.64 | $8,460.00 |
DisclosureSEC source: 0001731122-21-000941 · ownership.xml · nonDerivative · entry 3 FAVUS ELLIOT · CIK 0001608022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2021 Filed May 26, 2021 01:30 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | Exercise / conversionCommon Stock | 50,000 | $0.92 | $46,000.00 |
DisclosureSEC source: 0001731122-21-000941 · ownership.xml · nonDerivative · entry 2 FAVUS ELLIOT · CIK 0001608022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2021 Filed May 26, 2021 01:30 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | Exercise / conversionCommon Stock | 37,500 | $1.20 | $45,000.00 |
DisclosureSEC source: 0001731122-21-000941 · ownership.xml · nonDerivative · entry 1 FAVUS ELLIOT · CIK 0001608022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2021 Filed Feb 27, 2021 02:31 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | Exercise / conversionStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $3.28 | $0.00 |
DisclosureSEC source: 0001731122-21-000308 · ownership.xml · derivative · entry 5 FAVUS ELLIOT · CIK 0001608022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2026-09-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2021 Filed Feb 27, 2021 02:31 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | Exercise / conversionStock Option (Right to Buy) · Derivative | 45,500 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0001731122-21-000308 · ownership.xml · derivative · entry 4 FAVUS ELLIOT · CIK 0001608022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,500 shares Expires 2028-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options vested upon the achievement of 50% enrollment in the Company's Alzheimer's disease and Parkinson's disease dementia clinical trials. Read SEC document |
| February 24, 2021 Filed Feb 27, 2021 02:31 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | SaleCommon Stock | 145,500 | $12.66 | $1,841,855.40 |
DisclosureSEC source: 0001731122-21-000308 · ownership.xml · nonDerivative · entry 3 FAVUS ELLIOT · CIK 0001608022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| February 24, 2021 Filed Feb 27, 2021 02:31 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | Exercise / conversionCommon Stock | 100,000 | $3.28 | $328,000.00 |
DisclosureSEC source: 0001731122-21-000308 · ownership.xml · nonDerivative · entry 2 FAVUS ELLIOT · CIK 0001608022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2021 Filed Feb 27, 2021 02:31 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | Exercise / conversionCommon Stock | 45,500 | $2.58 | $117,390.00 |
DisclosureSEC source: 0001731122-21-000308 · ownership.xml · nonDerivative · entry 1 FAVUS ELLIOT · CIK 0001608022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 19:22 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $5.49 | $0.00 |
DisclosureSEC source: 0001731122-21-000008 · ownership.xml · derivative · entry 1 FAVUS ELLIOT · CIK 0001608022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2030-12-30 Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 23:00 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.96 | $0.00 |
DisclosureSEC source: 0001731122-20-000020 · ownership.xml · derivative · entry 1 FAVUS ELLIOT · CIK 0001608022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-01-06 Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 21:33 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 45,500 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0001615774-18-010447 · s113108_form4.xml · derivative · entry 1 FAVUS ELLIOT · CIK 0001608022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,500 Underlying: Common Stock · 45,500 shares Expires 2028-10-01 F1 · derivative.exercise_date: The options shall vest upon the achievement of 50% enrollment in the Company's Alzheimer's disease and Parkinson's disease dementia clinical trials. Read SEC document |
| September 22, 2016 Filed Sep 26, 2016 21:24 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $3.28 | $0.00 |
DisclosureSEC source: 0001615774-16-007390 · s104219_form4.xml · derivative · entry 1 FAVUS ELLIOT · CIK 0001608022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2026-09-22 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.